[CAS NO. 1116745-06-2] DuocarmycinDMfreebase
PRODUCTS SPECIFICATIONS [1116745-06-2]
DESCRIPTION [1116745-06-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 463.96 |
| Molecular Formula | C26H26ClN3O3 |
| SMILES | O=C(N1C[C@@H](CCl)C2=C1C=C(O)C3=CC=CC=C23)C(N4)=CC5=C4C=CC(OCCN(C)C)=C5 |
Summary
IC50 & Target
|
Daunorubicins/Doxorubicins |
In Vitro
The Duocarmycins and CC-1065 are members of a class of DNA minor groove, AT-sequence selective, and adenine-N3 alkylating agents, isolated from
Streptomyces sp.
that exhibit extremely potent cytotoxicity against the growth of cancer cells grown in culture
[2]
.
Duocarmycin shows cytotoxicity to several human cancer cells, with IC
50
of 22, 13.8, 3.87, 15.4, and 7.31 pM for HT-29, CL1-5, Caski, EJ, and LS174T, respectively
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Solvent & Solubility
DMSO : 50 mg/mL ( 107.77 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1554 mL | 10.7768 mL | 21.5536 mL |
| 5 mM | 0.4311 mL | 2.1554 mL | 4.3107 mL |
| 10 mM | 0.2155 mL | 1.0777 mL | 2.1554 mL |
References
- [1] Patil PC, et al. A Short Review on the Synthetic Strategies of Duocarmycin Analogs that are Powerful DNA Alkylating Agents. Anticancer Agents Med Chem. 2015;15(5):616-630.
- [2] Koch MF, et al. Structural, Biochemical, and Computational Studies Reveal the Mechanism of Selective Aldehyde Dehydrogenase 1A1 Inhibition by Cytotoxic Duocarmycin Analogues. Angew Chem Int Ed Engl. 2015 Nov 9;54(46):13550-4.
- [3] Chen KC, et al. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue. Mol Pharm. 2013;10(5):1773-1782.
- [4] Chen KC, Schmuck K, Tietze LF, Roffler SR. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue. Mol Pharm. 2013;10(5):1773-1782.
